Premium
Regulation of redox signaling in HIF‐1‐dependent tumor angiogenesis
Author(s) -
Manuelli Valeria,
Pecorari Chiara,
Filomeni Giuseppe,
Zito Ester
Publication year - 2022
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.16110
Subject(s) - angiogenesis , crosstalk , transcription factor , microbiology and biotechnology , carcinogenesis , hypoxia (environmental) , signal transduction , chemistry , neovascularization , cancer research , biology , biochemistry , oxygen , gene , physics , organic chemistry , optics
Angiogenesis is the process of blood vessel growth. The angiogenic switch consists of new blood vessel formation that, in carcinogenesis, can lead to the transition from a harmless cluster of dormant cells to a large tumorigenic mass with metastatic potential. Hypoxia, that is, the scarcity of oxygen, is a hallmark of solid tumors to which they adapt by activating hypoxia‐inducible factor‐1 (HIF‐1), a transcription factor triggering de novo angiogenesis. HIF‐1 and the angiogenic molecules that are expressed upon its activation are modulated by redox status. Modulations of the redox environment can influence the angiogenesis signaling at different levels, thereby impinging on the angiogenic switch. This review provides a molecular overview of the redox‐sensitive steps in angiogenic signaling, the main molecular players involved, and their crosstalk with the unfolded protein response. New classes of inhibitors of these modulators which might act as antiangiogenic drugs in cancer are also discussed.